|
|
| (11) | Liudijimo numeris | C 3533792 |
| (68) | Patento numeris | 3533792 |
| (21) | Paraiškos papildomos apsaugos liudijimui gauti numeris | PA 2021 525 |
| (22) | Paraiškos papildomos apsaugos liudijimui gauti padavimo data | 2021-11-03 |
| (41) | Paraiškos papildomos apsaugos liudijimui gauti paskelbimo data | 2021-11-25 |
| Liudijimo paskelbimo data | 2024-07-10 | |
| (24) | Liudijimo įsigaliojimo data | 2033-06-05 |
| (71) |
Sloan Kettering Institute For Cancer Research,
1275 York Avenue, New York, NY 10065,
US
Aragon Pharmaceuticals, Inc. , 10990 Wilshire Blvd. Suite 440, Los Angeles, CA 90024, US |
| (73) |
Sloan Kettering Institute For Cancer Research,
1275 York Avenue, New York, NY 10065,
US
Aragon Pharmaceuticals, Inc. , 10990 Wilshire Blvd. Suite 440, Los Angeles, CA 90024, US |
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (93) | EU/1/18/1342, 2019-01-14 |
| (94) | 2034-01-16 |
| (95) | Apalutamidas |
| PAL išduotas |